List of Excipients in Branded Drug MIGRANAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	MIGRANAL	dihydroergotamine mesylate	0187-0245	ANHYDROUS DEXTROSE
Bausch Health US LLC	MIGRANAL	dihydroergotamine mesylate	0187-0245	CAFFEINE
Bausch Health US LLC	MIGRANAL	dihydroergotamine mesylate	0187-0245	CARBON DIOXIDE
Bausch Health US LLC	MIGRANAL	dihydroergotamine mesylate	0187-0245	WATER

Migranal Excipient Strategy and Commercial Opportunities for Dihydroergotamine Nasal Spray

Last updated: August 20, 2026

Migranal is a dihydroergotamine mesylate nasal spray whose commercial opportunity is tied to reformulation, device performance, and generic or lifecycle replacement rather than simple excipient substitution. The reference product delivers 0.5 mg of dihydroergotamine mesylate per spray and uses a relatively simple aqueous formulation containing caffeine, anhydrous glucose, carbon dioxide, citric acid, nitrogen, and purified water. The strongest opportunities are a stable multidose nasal system, improved intranasal deposition, lower preservative burden, easier administration, and differentiated products for patients who cannot tolerate oral triptans or injectable dihydroergotamine.

What is Migranal and how is it administered?

Migranal is the nasal-spray formulation of dihydroergotamine mesylate, an ergot alkaloid used for the acute treatment of migraine with or without aura. It is administered as one spray into each nostril, followed by a second spray into each nostril 15 minutes later. The total dose is four sprays, or 2 mg of dihydroergotamine mesylate, unless otherwise directed by the prescribing information. The product is not intended for prophylactic migraine treatment. [1]

Migranal product profile

Attribute	Migranal profile
Active ingredient	Dihydroergotamine mesylate
Dosage form	Nasal spray solution
Strength	0.5 mg per spray
Maximum labeled dose	2 mg per attack
Route	Intranasal
Therapeutic category	Acute migraine treatment
Original regulatory pathway	FDA-approved NDA
Key formulation issue	Variable nasal absorption and device-dependent delivery
Primary commercial substitutes	Injectable dihydroergotamine, oral triptans, gepants, ditans, and alternative DHE nasal systems

Dihydroergotamine acts primarily through serotonin receptor agonism and other vasoconstrictive mechanisms. Its pharmacology creates meaningful contraindications and drug-interaction restrictions, including use with potent CYP3A4 inhibitors and certain cardiovascular conditions. A reformulated product must preserve the established acute-migraine indication while avoiding excipient changes that create new safety or tolerability concerns. [1]

What excipients are used in Migranal?

Migranal contains an aqueous excipient system designed to maintain pH, support chemical stability, and enable nasal delivery. The listed inactive ingredients are caffeine, anhydrous glucose, carbon dioxide, citric acid, nitrogen, and purified water. [1,2]

Functional role of the Migranal excipients

Excipient	Likely formulation function
Purified water	Primary solvent and vehicle
Citric acid	Acidifying agent and pH adjustment
Carbon dioxide	Dissolved gas and formulation or packaging-process aid
Nitrogen	Headspace or oxygen-displacement gas
Anhydrous glucose	Tonicity and osmolality adjustment
Caffeine	Formulation component with potential absorption or pharmacologic relevance

Caffeine requires particular attention. It is not a conventional inert tonicity agent. Caffeine has recognized pharmacologic activity in migraine products and may affect perceived efficacy, tolerability, or product differentiation. A developer removing caffeine cannot assume that the resulting product is therapeutically equivalent without assessing pharmacokinetics, local tolerability, clinical effect, and regulatory comparability.

The gas components also create development complexity. Carbon dioxide and nitrogen may influence oxygen exposure, pH, headspace composition, spray performance, and container closure integrity. Their presence indicates that the original product was designed with a controlled manufacturing and packaging environment rather than as a simple aqueous nasal solution.

What excipient strategy is most attractive for a Migranal replacement?

The strongest strategy is a low-complexity, preservative-free aqueous formulation paired with a high-performance multidose nasal device. The formulation should prioritize four targets:

1. Chemical stability of dihydroergotamine mesylate.
2. Nasal tolerability during repeated sprays.
3. Consistent delivered dose across the product shelf life.
4. Reproducible deposition in the nasal cavity.

1. pH and buffer selection

Dihydroergotamine mesylate is formulated in an acidic aqueous environment. Citric acid provides a straightforward path for pH control, but a broader buffer system could improve resistance to pH drift during storage. Candidate systems include citrate, acetate, or other low-capacity buffers compatible with nasal administration.

The commercial tradeoff is direct. A stronger buffer may improve chemical stability but increase nasal irritation or alter mucociliary function. A weakly buffered system may improve tolerability but permit pH movement after repeated container use or exposure to air.

A developer should avoid unnecessary buffer capacity. The target should be the lowest buffer concentration that maintains the validated pH range through shelf life and in-use testing.

2. Tonicity adjustment

Anhydrous glucose provides osmolality adjustment in the reference formulation. Alternatives could include sodium chloride, glycerol, sorbitol, or other pharmaceutically accepted tonicity agents. The choice affects viscosity, spray plume, local tolerability, and microbial risk.

Sodium chloride is familiar and inexpensive, but ionic strength can affect drug stability and nasal sensation. Polyols may provide a softer sensory profile but can increase viscosity or create manufacturing and microbial-control considerations. A nonionic tonicity system may be commercially attractive if it improves comfort without changing absorption.

A replacement product should target near-isotonic or clinically justified mildly hypotonic or hypertonic conditions. The relevant performance endpoint is not osmolality alone. Spray sensation, drip, retention, clearance, and systemic exposure should be measured together.

3. Preservative-free design

A preservative-free Migranal replacement has commercial value because repeated nasal exposure to preservatives can cause irritation and may reduce patient acceptance. The principal challenge is microbiological control in a multidose package.

Possible approaches include:

• A unit-dose container.
• A mechanically sealed multidose pump.
• A sterile or aseptically filled device.
• A container closure that prevents backflow and microbial ingress.
• A formulation with validated antimicrobial protection without conventional preservatives.

A preservative-free product is most commercially credible when the device itself provides the barrier. The value proposition is stronger if the product also reduces priming steps, minimizes waste, and maintains dose uniformity after intermittent use.

4. Surfactants and wetting agents

Surfactants may improve wetting, solubilization, or spray reproducibility, but they can increase nasal irritation and alter epithelial permeability. A developer should treat surfactants as performance-enabling excipients rather than default formulation components.

If solubility is adequate in the existing acidic aqueous system, a surfactant-free formulation may be preferable. If a surfactant is required, the product should use the lowest effective concentration and characterize local tolerability, extractables, adsorption to device materials, and delivered-dose consistency.

5. Viscosity modifiers

Increasing viscosity may improve nasal residence time and reduce runoff. Candidate materials include hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, or selected mucoadhesive polymers. These materials can also create commercial disadvantages:

• Broader spray droplets.
• Greater device clogging risk.
• Higher actuation force.
• More variable plume geometry.
• Increased residual volume.
• Potentially slower or less predictable absorption.

For DHE, a high-viscosity nasal gel is not automatically superior. Systemic exposure must remain rapid enough for acute migraine treatment. A modest viscosity increase may be useful only if it improves deposition without delaying absorption.

What formulation patents and intellectual-property barriers affect Migranal opportunities?

The principal IP risk is likely to arise from the combination of formulation, container closure, and nasal-delivery device rather than from the basic use of dihydroergotamine mesylate. Dihydroergotamine is an established active ingredient, and the original Migranal product has been on the market for decades. Basic composition claims covering water, citric acid, glucose, caffeine, and gases are generally less defensible than claims directed to a specific concentration range, stability profile, packaging configuration, or delivery method.

High-value claim categories

A lifecycle developer should evaluate claims covering:

• Dihydroergotamine concentration and pH ranges.
• Caffeine-containing or caffeine-free compositions.
• Preservative-free multidose nasal systems.
• Oxygen-controlled or inert-gas packaging.
• Spray plume geometry and droplet-size distribution.
• Nasal deposition in the upper nasal cavity.
• Device priming and dose-counting mechanisms.
• Stability after repeated actuation.
• Combination use with another migraine medicine.
• Methods for treating patients with poor oral absorption or nausea.

A device-led product may have stronger protection than a conventional excipient patent. Trudhesa, an alternative DHE nasal product approved by FDA in 2021, illustrates the commercial importance of delivery technology. Its Precision Olfactory Delivery system is designed to deliver drug to the upper nasal space. [3,4]

Orange Book and paragraph IV considerations

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and regulatory exclusivity. A generic applicant evaluating a dihydroergotamine nasal spray would need to assess current Orange Book listings, product-specific exclusivity, reference-product status, and any applicable patent certifications. [5]

Potential paragraph IV disputes could involve:

• Formulation patents.
• Device patents.
• Use patents directed to a particular patient population.
• Method-of-treatment claims involving upper-nasal deposition.
• Manufacturing or packaging claims.

A generic that reproduces the reference formulation but uses a materially different device may face fewer formulation barriers but greater bioequivalence and device-performance requirements. A product that uses a different excipient system may avoid some composition claims while increasing the burden of comparative clinical and pharmacokinetic evidence.

When does Migranal lose exclusivity and what is its current FDA status?

Migranal received FDA approval in 1997. Its original small-molecule regulatory exclusivity expired long ago. The commercial question is therefore not the end of original exclusivity but whether current patents, device rights, discontinued-product status, or regulatory requirements create practical barriers to market entry.

Migranal has been listed as discontinued in FDA and drug-information records, while dihydroergotamine remains available through other dosage forms and products. [2,5] A discontinued reference product can complicate generic development because an applicant may need to establish a suitable reference product and demonstrate pharmaceutical equivalence or pursue an alternative regulatory pathway.

Key regulatory milestones

Event	Date
Original Migranal approval	1997
Original small-molecule exclusivity	Expired
Trudhesa approval	September 2021
Current market opportunity	Replacement, generic, or improved DHE nasal delivery

The regulatory pathway depends on the proposed product. An identical nasal spray may be evaluated through an abbreviated application if FDA recognizes an appropriate reference product. A materially different formulation or device may require a new drug application supported by pharmacokinetic, clinical, device, and human-factors data.

What commercial opportunities exist for Migranal excipients?

Opportunity 1: Preservative-free multidose spray

This is the clearest formulation opportunity. A preservative-free product can target patients with nasal sensitivity and improve chronic usability for intermittent migraine attacks. The commercial advantage depends on a device that prevents contamination without imposing complex handling.

Opportunity 2: Improved nasal retention

A mild mucoadhesive formulation could reduce runoff and improve local deposition. The product should avoid excessive viscosity because acute migraine products depend on rapid and predictable absorption.

Opportunity 3: Caffeine-free DHE nasal spray

Removing caffeine could appeal to patients who experience insomnia, palpitations, anxiety, or caffeine-related adverse effects. The development risk is that caffeine may contribute to the reference product's clinical or pharmacokinetic profile. A caffeine-free version would need a clear regulatory and clinical differentiation strategy.

Opportunity 4: Lower-irritation formulation

A formulation with optimized pH, osmolality, and excipient concentration could compete on comfort. Patient-reported burning, taste, throat drip, and nasal congestion are commercially relevant attributes in a nasal migraine product.

Opportunity 5: Device-formulation integration

A redesigned pump can control plume geometry, droplet size, actuation volume, and deposition. This opportunity is commercially stronger than a stand-alone excipient change because it can support device claims, method-of-use claims, and measurable performance advantages.

Opportunity 6: Lower-cost generic or authorized alternative

If a viable reference pathway exists, a lower-cost product could target patients and payers facing high prices for branded or device-protected DHE nasal products. The main barriers are not the cost of the active ingredient but bioequivalence, device reproducibility, packaging, and regulatory evidence.

How does Migranal compare with Trudhesa?

Factor	Migranal	Trudhesa
Active ingredient	Dihydroergotamine mesylate	Dihydroergotamine mesylate
Route	Intranasal	Intranasal
Delivery concept	Conventional nasal spray	Upper-nasal delivery system
Product differentiation	Established formulation and brand history	Device-led deposition strategy
Excipient opportunity	Reformulation and tolerability	Compatibility with specialized device
IP exposure	Legacy product and possible historical rights	Device, formulation, and method-of-use rights
Commercial positioning	Replacement or generic opportunity	Branded differentiated delivery

Trudhesa raises the competitive standard for new DHE nasal products. A new Migranal-based product would need either lower cost, better tolerability, easier administration, broader access, or a measurable delivery advantage. A minor excipient change without improved clinical or usability performance would have limited commercial value.

What manufacturing and geographic barriers affect commercialization?

Manufacturing controls are central to product quality. Dihydroergotamine nasal spray requires control of:

• Drug concentration.
• pH and osmolality.
• Dissolved oxygen and headspace gases.
• Container closure integrity.
• Pump actuation force.
• Delivered volume.
• Droplet-size distribution.
• Microbial quality.
• Extractables and leachables.
• In-use stability.

Geographic expansion also requires jurisdiction-specific assessment of excipient acceptability, nasal-device classification, pharmaceutical equivalence standards, and local patent rights. The FDA pathway does not determine European, Canadian, Japanese, or other national approval requirements. A formulation using novel mucoadhesive polymers or preservative-free multidose packaging may encounter different regulatory expectations across markets.

What generic entry risks exist for Migranal?

Generic entry risk is moderate from a chemistry perspective but can be high from a product-development perspective. Dihydroergotamine is well characterized, and the active ingredient is not novel. The more difficult elements are nasal delivery and product sameness.

The main risks are:

1. No simple reference product pathway if the original product is discontinued.
2. Difficulty matching delivered dose and spray characteristics.
3. Device patents associated with competing products.
4. Clinical differences caused by caffeine removal or excipient substitution.
5. Microbiological risk in preservative-free multidose systems.
6. Manufacturing variability in pump performance.
7. Limited payer willingness to reimburse a product without a clear advantage over oral migraine therapies.

Key Takeaways

• Migranal contains dihydroergotamine mesylate in an aqueous nasal formulation with caffeine, anhydrous glucose, carbon dioxide, citric acid, nitrogen, and purified water.
• Its original regulatory exclusivity expired long ago; current opportunity depends on product status, reference-product availability, patents, and device requirements.
• The highest-value excipient strategies are preservative-free delivery, optimized pH and osmolality, reduced nasal irritation, and controlled viscosity.
• Caffeine removal is commercially attractive but creates a comparability and clinical-development issue.
• Device performance is as important as formulation composition for nasal DHE products.
• Trudhesa has shifted competition toward upper-nasal deposition and device-led differentiation.
• A generic or replacement product needs a credible strategy for bioequivalence, spray characterization, microbial control, and container closure integrity.
• Stronger intellectual-property opportunities are likely to involve formulation ranges, packaging, device architecture, deposition, and method-of-use claims rather than the basic DHE composition.

FAQs

Can caffeine be removed from Migranal without creating a new product?

Removing caffeine may change pharmacokinetics, tolerability, or clinical performance. A caffeine-free formulation could be developed, but it would require comparative evidence and may not qualify as a straightforward equivalent product.

Is a preservative-free Migranal formulation commercially feasible?

Yes, if the multidose device prevents microbial ingress and maintains dose uniformity. Unit-dose packaging is simpler microbiologically but can increase packaging cost and reduce convenience.

Which excipient is most important for Migranal nasal absorption?

No single excipient determines absorption. pH, osmolality, spray volume, droplet size, viscosity, nasal deposition, and mucosal tolerability operate as an integrated system.

Does a new DHE nasal spray need to copy the Migranal excipients?

Not necessarily. A different excipient system may be possible, but the sponsor must establish safety, stability, delivered-dose performance, and the appropriate FDA regulatory pathway.

Are biosimilar issues relevant to Migranal?

No. Dihydroergotamine mesylate is a small molecule, so the relevant competitive pathways are generic, hybrid, or new drug applications rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). Migranal (dihydroergotamine mesylate) nasal spray prescribing information.

2. DailyMed. (n.d.). Migranal: Dihydroergotamine mesylate nasal spray. National Library of Medicine.

3. U.S. Food and Drug Administration. (2021). FDA approves new nasal spray medication for acute migraine treatment. FDA.

4. Impel Pharmaceuticals. (2021). Trudhesa (dihydroergotamine mesylate) nasal spray prescribing information.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.